ABB  Vol.4 No.7 C , July 2013
Intrathecal IgG synthesis in relapsing-remitting multiple sclerosis (MS) is decreased by natural human alpha interferon
ABSTRACT
Intrathecal IgG synthesis (IT IgG Syn) is an established biomarker used for the diagnosis of multiple sclerosis (MS). Earlier studies used this biomarker to assess the impact of 2 different synthetic forms of interferon alpha (IFN-α) in chronic progressive MS. Unexpectedly, IT IgG synthesis was increased by this treatment. For the first time, we have assessed this parameter in relapsing-remitting patients to measure the impact of natural IFN-α treatment in a doseranging study in six dosage groups (5, 10, 15, 20, 25, & 30 MIU). We have found that IFN-α normalized IT IgG Synthesis at 12 weeks treatment for all dosage groups. Two weeks after stopping IFN-α results rose slightly. At 52 weeks, 28 weeks after stopping IFN-a results revealed cessation of IT IgG Synthesis in half of the patients (15, 20, 25 MIU weekly). These results reflect different outcomes for relapsing-remitting patients vs. chronic progressive patients. They may, however, reflect differences in the biological properties of the interferon products used. An optimal range of dosage with natural human IFN-α dosage for MS is suggested by the results.

Cite this paper
Sheremata, W. , Sazant, A. , Riesgo, V. and Burns, A. (2013) Intrathecal IgG synthesis in relapsing-remitting multiple sclerosis (MS) is decreased by natural human alpha interferon. Advances in Bioscience and Biotechnology, 4, 1-5. doi: 10.4236/abb.2013.47A3001.
References
[1]   Tourtellotte, W.W., Staugaitis, S., Walsh, M.J., Shapshack, P., et al. (1985) The basis of intra-blood-brainbarrier IgG synthesis. Annals of Neurology, 17, 21-27. doi:10.1002/ana.410170107

[2]   Polman, C.H., Reingold, S.C., Banwell, B., Clanet, M., et al. (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology, 69, 292-302. doi:10.1002/ana.22366

[3]   Knobler, R. L. S., Panitch, H., Braheny, S. L., Sipe, J. C., et al. (1984) Systemic alpha-interferon therapy of multiple sclerosis. Neurology, 32, 1273-1279. doi:10.1212/WNL.34.10.1273

[4]   Panitch, H.S., Francis, G.S, Hooper, C.J., et al. (1983) Serial immunological studies in multiple sclerosis patients treated systemically with human alpha interferon. Annals of Neurology, 18, 434-438. doi:10.1002/ana.410180404

[5]   Kastrukoff, L.F., Oger, J.J.-F., Tourtellotte, W.W., Sack, S.L., Berkowitz, J. and Paty D.W. (1991) Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. II. Immunologic evaluation. Neurology, 41, 1936-1941. doi:10.1212/WNL.41.12.1936

[6]   Kinnunen, E., Timonen, T., Pirttila, T., Kalliomaki, P. et al. (1993) Effects of recombinant alpha-2b-interferon in patients with progressive MS. Acta Neurologica Scandinavica, 87, 457-460.

[7]   Sheremata, W.A. and Minagar, A. (2004) Management of Interferon-beta1b (Betaseron) failures with Interferonalfan3 (Alferon). In: Hommes, O. R. and Comi, G., Ed., Early Indicators, Early Treatments, Neuroprotection in Multiple Sclerosi, Topics in Neuroscience, Springer Verlag, Milano, 191-195. doi:10.1007/978-88-470-2117-4_20

[8]   Strander, H., Cantell, H., Carlstrom, G., Jakobsson, P.A. (1973) Clinical and laboratory investigations on man: Systemic administration of potent interferon to man. Journal of the National Cancer Institute, 51, 733-743

[9]   Miro, J., Aguayo, P., Alvarez, C., et al. (1992) Intrathecal immunoglobulin synthesis in multiple sclerosis: Effect of corticosteroids and azathioprine. European Neurology, 32, 349-353. doi:10.1159/000116859

[10]   Milanese, C., Salmaggi, A., La Mantia, I., Campi, A., et al. (1990) Double blind study of intrathecal beta-interferon in multiple sclerosis: clinical and laboratory results. Journal of Neurology, Neurosurgery & Psychiatry, 53, 354-557. doi:10.1136/jnnp.53.7.554

[11]   Villar, L.M., Garcia-Sanchez, M.I., Costa-Frossard, L, Espino, M, et al. (2012) Immunological markers of optimal response to natalizumab in multiple sclerosis. Archives of Neurology, 68, 191-197. doi:10.1001/archneurol.2011.971

[12]   Brandao, C.O., Ruocco. H.H., Santos Farias, A, Oliveira, C., et al. (2005) Cytokines and intrathecal IgG synthesis in multiple sclerosis patients during clinical remission. Arquivos de Neuro-Psiquiatria, 63, 914-919. doi:10.1590/S0004-282X2005000600002

[13]   Ruocco, H.H., Brandao, C.O., Farias, A.S, Oliveira, E.C, et al. (2012) Quantitative MRI and cerebrospinal fluid inflammatory mediators in Brazilian patients with relapsing-remitting multiple sclerosis before and after treatment with immunomodulators: a g longitudinal study. Neuroimmunomodulation, 19, 277-282. doi:10.1159/000335889

[14]   Prineas, J.W., Kwon, E.E., Cho, E.-S., Sharer, L.R., et al. (2001) Immunopathology of secondary-progressive multiple sclerosis. Annals of Neurology, 50, 646-657. doi:10.1002/ana.1255

[15]   Serafini, B., Rosicarelli, B., Magliozzi, R., Stigliano E., and Aloisi, F. (2006) Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathology, 14, 164-174.

[16]   Rice, G.P.A., Woelfel, E.L., Talbot, P.J., Braheny, S.L., et al. (1985) Immunological complications in multiple sclerosis patients receiving interferon. Annals of Neurology, 18, 439-442. doi:10.1002/ana.410180405

[17]   Gaits G and Huber C. (1988) The biology of interferon actions. Blut, 56, 193-199. doi:10.1007/BF00320105

[18]   Kastrukoff, L.F., Oger, J.J., Hashimoto, S.L., Sacks. S.L., et al. (1990) Systemic lymphoblastoid interferon therapy in chronic progressive multiple Sclerosis. I. Clinical and MRI evaluation. Neurology, 40, 479-486. doi:10.1212/WNL.40.3_Part_1.479

[19]   Sheremata, W., Harrington, W., Tornes, L., Ortega, M., McCarthy M. (2011) Therapeutic response to human interferon-alpha-n3 but failure with recombinant interferonalpha-2b in HAM.TSP. Multiple Sclerosis, 17, S280.

[20]   Fattovich, G., Giustina, G., Favarato, S. and Ruol A. (1996) A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. Journal of Hepatology, 24, 38-47. doi:10.1016/S0168-8278(96)80184-X

 
 
Top